Bharat Biotech
-
DCGI approves Covaxin for phase 2/3 trials on children
News | May 13, 2021, 11:20 AM ISTThe DGCI has approved Bharat Biotech's COVID-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
-
DGCI approves Bharat Biotech's Covaxin for phase 2/3 trials on children
India | May 13, 2021, 11:45 AM ISTCovaxin is currently being administered to the people in the country along with Covishield. Hyderabad-based Bharat Biotech is manufacturing Covaxin.
-
Covishield monthly production to touch 10 crore by August, Covaxin 7.8 crore
India | May 13, 2021, 07:55 AM ISTSerum Institute and Bharat Biotech have submitted to the Centre that they can ramp up production of Covishield and Covaxin to 10 crore and 7.8 crore doses, respectively, by August.
-
Super 100: Covaxin centres in Delhi closed as Bharat Biotech refused to provide doses: Manish Sisodia
News | May 12, 2021, 10:12 PM ISTSeveral Covid-19 vaccination centres in Delhi are closed due to shortage of vaccine. Manish Sisodia has claimed that Covaxin manufacturer Bharat Biotech has declined to provide vaccine.
-
Disheartening to hear some states complaining about Covaxin supply: Bharat Biotech
India | May 12, 2021, 09:41 PM ISTBharat Biotech co-founder and Joint MD Suchitra Ella tweeted this on Wednesday amid reports of some states voicing their unhappiness over supplies.
-
Bharat Biotech to begin vaccine trial for those between 2-18 years-old | Experts view
News | May 13, 2021, 05:52 PM ISTVaccine maker Bharat Biotech will soon begin the clinical trial for those falling between the age of 2-18 years old.
-
Polio vaccine maker BIBCOL to manufacture Covaxin at UP's Bulandshahr plant
India | May 13, 2021, 10:52 AM ISTBIBCOL will manufacture 2 crore doses of Covaxin every month at its Bulandshahar plant in Uttar Pradesh.
-
Expert panel approves Covaxin for phase 2/3 trials on children
India | May 12, 2021, 11:14 AM ISTThe trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
-
Fact Check: Bharat Biotech's Covaxin approved for children above 12 years?
India | May 10, 2021, 12:37 PM ISTGovernment has said that a tweet claiming that Covaxin has been approved for children above 12 years of age is fake.
-
Bharat Biotech commences direct supply of 'Covaxin' to 14 states
India | May 10, 2021, 12:13 PM ISTThe company is supplying vaccines to Andhra Pradesh, Assam, Chhattisgarh, Gujarat, Jammu & Kashmir, Jharkhand, Madhya Pradesh, Odisha, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal.
-
Covishield production in full swing in Pune, will return to India soon, says Adar Poonawalla
India | May 02, 2021, 09:37 AM ISTSerum Institute of India CEO Aadar Poonawalla has said that the production of COVID-19 vaccine Covishield is in full swing in Pune and he will review the operations once he is back in the country.
-
Covaxin price reduced from Rs 600 to Rs 400 per dose for states, says Bharat Biotech
India | Apr 29, 2021, 06:15 PM ISTCovaxin vaccine maker Bharat Biotech on Thursday announced a drop in the price of its vaccine that will be made available to the state governments.
-
Maharashtra govt writes to SII, Bharat Biotech about their demand of COVID-19 vaccines
India | Apr 28, 2021, 11:16 AM ISTMaharashtra remains one of the worst-COVID-affected states in the country. As many as 66,358 new cases, 895 deaths and 67,752 recoveries were reported on Tuesday. The total case tally stands at 44,100,85.
-
Reduce vaccine price: Govt tells Serum Institute, Bharat Biotech
India | Apr 26, 2021, 08:16 PM ISTThe move has come days ahead of India's planned drive to inoculate all aged above 18. The vaccination drive is set to begin May 1.
-
Bharat Biotech seeks DCGI's nod to extend shelf life of Covaxin
India | Apr 25, 2021, 05:01 PM ISTBharat Biotech has written to India's drug regulator seeking extension of the shelf-life of its indigenously developed COVID-19 vaccine Covaxin from six to 24 months, sources said on Sunday.
-
Covaxin to cost Rs 600 per dose for state hospitals, Rs 1,200 to private ones
India | Apr 24, 2021, 11:06 PM ISTCovaxin, India's indigeniously developmed coronavirus vaccine, will be sold at Rs 600 per dose for state hospitals and Rs 1,200 per dose for private hospitals, vaccine maker Bharat Biotech has informed.
-
COVID: Andhra Pradesh govt places order for 4.08 cr doses each of Covaxin, Covishield
India | Apr 24, 2021, 06:52 PM ISTGovt Principal Secy (Covid Management and Vaccination) wrote letters to Bharat Biotech MD Krishna Yella and Serum Institute of India Limited CEO Adar Poonawalla in this regard.
-
'Understand India's pharmaceutical needs': US to consider lifting ban on vaccine raw material supply
World | Apr 20, 2021, 02:50 PM ISTThe Biden administration has conveyed to India that they understand India's pharmaceutical requirements and has promised to review embargo on Covid-19 vaccine raw material.
-
Govt to provide Rs 4,500 cr booster to SII, Bharat Biotech for ramping up Covid vaccine production
India | Apr 20, 2021, 12:30 PM ISTCOVID-19 vaccine: SII will supply 200 million doses and Bharat Biotech is to supply another 90 million doses to the government by July at a pre-agreed rate of Rs 150 per dose.
-
DGCI grants approval for clinical trials for third dose of Covaxin
India | Apr 02, 2021, 01:03 PM ISTThe expert panel of India's drug regulator, DCGI, has permitted Bharat Biotech to give the third dose of Covaxin to a few volunteers in its clinical trials of the COVID-19 vaccine.